A Single-Center Phase I Dose Escalation/Response Trial to Evaluate Safety, Tolerability, and Anti-Tumor Efficacy of Intra-Arterial CBL0137 for Patients With Advanced Extremity Melanoma or Sarcoma
Phase of Trial: Phase I
Latest Information Update: 08 Jul 2019
Price : $35 *
At a glance
- Drugs CBLC 137 (Primary)
- Indications Malignant melanoma; Sarcoma
- Focus Adverse reactions
- 03 Jul 2019 Status changed from not yet recruiting to recruiting.
- 19 Jun 2019 Planned initiation date changed from 28 May 2019 to 28 Jul 2019.
- 07 May 2019 Planned initiation date changed from 28 Apr 2019 to 28 May 2019.